Table 3.

Galectin-3 concentration at baseline and on the follow-up visit in the subgroup of patients without endpoints during observation.

No Endpoints during Follow Up	Gal-3 Concentration (ng/mL) at Baseline	Gal-3 Concentration (ng/mL) on the Follow-Up Visit	p-Value
Subsequent MI	10.8 ± 6.1	8.8 ± 2.4	p = 0.03
Re-PCI	10.6 ± 5.8	8.6 ± 2.4	p = 0.04
CABG	11.1 ± 7.5	8.7 ± 2.5	p = 0.016
Stroke	10.7 ± 5.9	8.7 ± 2.3	p = 0.03

CABG—coronary artery bypass grafting, Gal-3—galectin-3, MI—myocardial infarction, PCI—percutaneous coronary interventions.